
Discover Altaviva™ therapy

The Altaviva™ implant is your convenient and hopeful next step, with automatic therapy delivery that can integrate seamlessly into your life—designed to keep you moving forward, wherever your journey leads. Unlike medications or injections that target bladder muscles, the Altaviva™ implant for urge urinary incontinence (UUI) targets the tibial nerve that helps control normal bladder function.1,2
How does it work?
- A small device is placed under the skin near the ankle and sends electrical pulses to the tibial nerve that is important in maintaining normal bladder function.1,2
- These pulses may help restore the communication pathways between the bladder and brain,1,2 which may help reduce urgency with leaks.3
- This treatment is called tibial neuromodulation, a proven therapy for reducing bladder control symptoms.3,4-8

A single procedure may help improve your quality of life:3
- Implanted in a single, outpatient procedure that lets you go home the same day
- Same-day therapy activation9
- MRI-ready from the start for full-body 1.5T or 3T scans*,10
- Long-lasting battery – designed to deliver up to 15 years of treatment†
For more information, visit www.medtronic.com/Altaviva.
In addition to risks related to surgery, complications can include pain at the implant site, lower leg pain, infection, and/or technical or device problems. Results vary. Talk to your doctor to see if the Altaviva™ system is right for you.
* MRI compatibility is subject to certain conditions. See approved labeling for details.
† Based on clinical and bench testing for expected therapy settings
1. Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromod. 2023;27:256–266.
2. Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder - techniques and efficacy. Int Urogynecol J. 2020;31:865–70.
3. Appendix B: Clinical Study Summary. M028929C001 RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N.
4. Peters KM, Carrico DJ, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–1443.
5. Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061.
6. Kobashi K, Nitti V, Margolis E, et al. A prospective study to evaluate efficacy using the NURO percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. J Urol. 2019;131:77–82.
7. Rogers A, Bragg S, Ferrante K, et al. Pivotal study of leadless tibial nerve stimulation with eCoin for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206:399–408.
8. Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, et al. A prospective study to assess the effectiveness and safety of the BlueWind system in the treatment of patients diagnosed with urgency urinary incontinence. Neurourol Urodyn. 2024;43:1491–1503.
9. M028930C001 RevC - Altaviva™ Model P7850N Neurostimulator Implant Manual.
10. M028949C001 RevC - MRI Guidelines for Altaviva™ Neurostimulator